Fujifilm acquires rights to Cynata cell therapy in GvHD

17 September 2019
fujifilm_large

Japanese conglomerate Fujifilm Corp (TYO: 4901) has exercised its license option to obtain rights to Cynata Therapeutics’ (ASX: CYP) CYP-001 in graft-versus-host disease (GvHD), a complication that occurs after bone marrow transplants.

Fujifilm will pay the Australian biotech company $3 million in cash as an upfront fee, with the Tokyo-based firm bearing responsibility for all costs of any further product development activities in relation to GvHD, along with responsibility for regulatory submissions and commercialization.

Up to $43 million in milestones

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical